Skandinaviska Enskilda Banken AB publ Has $31.86 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Skandinaviska Enskilda Banken AB publ lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 14.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,139,805 shares of the biopharmaceutical company’s stock after selling 192,601 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Pfizer were worth $31,863,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Olistico Wealth LLC acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer in the second quarter valued at $29,000. Creekmur Asset Management LLC bought a new stake in Pfizer during the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC grew its holdings in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer in the 2nd quarter worth about $34,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE opened at $29.42 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm’s 50-day simple moving average is $29.36 and its 200 day simple moving average is $28.22. The stock has a market cap of $166.71 billion, a price-to-earnings ratio of -490.25, a PEG ratio of 1.05 and a beta of 0.68. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.11.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.71%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, September 16th. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.